A Phase 2 interventional study of Lactobacillus Paracasei LPB27 and Maltodextrin in Eczema and Allergy, sponsored by The University of New South Wales. Recruiting at 1 site in Australia. Open to participants aged 3 Months to 3 Years. Per ClinicalTrials.gov, last updated 2025-06-03.
Sponsored by The University of New South Wales · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Eczema with a site in Australia — 4 open to participants now, 9 under way, 3 of them phase 3. Eczema · Australia.
Among the 41 studies in Eczema with a site in Australia, this one is the 35th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2024, is one of 16 in phase 2, and was the 38th registered.
507 studies on the registry are indexed under Eczema; 91 are open to participants now.
Browse Eczema studies →4 of the 41 studies in Eczema with a site in Australia are open now. Recruiting first, the newest first:
Inmagene LLC · Sites in Australia, United States, Canada and 1 more country
Ages 18–74
Alphyn Biologics · Sites in Australia
Ages 2+
Eli Lilly and Company · Sites in Australia, United States, Argentina and 10 more countries
Ages 6 mo–18 yrs
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 3 Months to 3 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 17 · Phase 3 22 · Phase 4 1
First in 2006; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 91 across 404 interventional studies indexed under Eczema.
Median enrollment 389 across the 40 interventional studies. Of the 31 that completed or were terminated, 25 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 41 have an industry lead sponsor. The 10 most frequent:
The University of New South Wales is the lead sponsor of 66 studies on the registry; 6 are open to participants now.
The University of New South Wales has 1 study filed under Eczema — fewer than ten, so there is no comparison to draw.
1 of the studies in Eczema with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03667651Phase 3University of MelbourneThe PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Eczema with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The LaCE study is a double-blind, randomised, placebo-controlled trial examining the effectiveness of the probiotic Lactobacillus paracasei LPB27 in treating eczema in young children.
Childhood eczema is a common and chronic, relapsing disease of the skin which affects up to 20% of the paediatric population. Eczema has significant impact on the quality of life of those affected. Its main symptoms are dry skin and intense itching.
There is currently no cure for eczema but there are treatments that try to relieve symptoms. These commonly include topical moisturisers and topical corticosteroids.
Although topical corticosteroids are effective in minimising symptoms, there is a prevailing and universal fear of using topical corticosteroids which is one of the main reasons for poor treatment compliance.
There have been emerging interests in prevention and treatment of eczema through modulation of the gut microbiome. The gut microbiome is a key regulator for the immune system and there is evidence that the composition of gut microbiome may reduce allergies by driving maturation of the immune system. It was shown that people with eczema have different bacteria in their gut compared to people without eczema. Therefore, this study's hypothesis is that administration of oral probiotics will benefit young children with eczema by improving their gut microbiome and quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Formulation: Lactobacillus paracasei LPB27 (10 billion cfu/ serve) and Maltodextrin (up to 1g). Dosage: 1mg daily for 12 weeks. Delivered orally through through breast milk, formula or solid food.
Dietary Supplement: Lactobacillus Paracasei LPB27
Formulation: Maltodextrin 1g Dosage: 1mg daily for 12 weeks. Delivered orally through through breast milk, formula or solid food.
Other: Maltodextrin
Probiotic
Placebo
Proportion of patients achieving treatment success
Clinically meaningful reduction (\>= 8.7 points) in SCORAD index between baseline and 12 weeks without the use of rescue medication (systemic immunosuppression and/or biologic agents)
Time frame: Between baseline and 12 weeks
Mean change in SCORAD index
Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in Scoring Atopic Dermatitis (SCORAD) index
Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
First use of rescue medication
Time from baseline to first use of rescue medication, up to 12 weeks
Time frame: From baseline to time of starting rescue medication (up to 12 weeks)
Mean change in RECAP
Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in Recap of Atopic Eczema (RECAP) score. The RECAP score ranges from a minimum of 0 to a maximum of 28, with higher scores indicating worse outcomes.
Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Mean change in IDQOL
Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in Infant Dermatitis Quality of Life (IDQOL) score. The IDQOL score ranges from a minimum of 0 to a maximum of 30, with higher scores indicating worse outcomes.
Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Mean change in EASI
Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in Eczema Area and Severity Index (EASI) score. The EASI score ranges from a minimum of 0 to a maximum of 72, with higher scores indicating worse outcomes.
Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Mean change in IGA
Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in Investigator Global Assessment for Atopic Dermatitis (IGA) score. The IGA score ranges from a minimum of 0 to a maximum of 4, with higher scores indicating worse outcomes.
Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Mean change in POEM
Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in Patient-Oriented Eczema Measure (POEM) score. The POEM score ranges from a minimum of 0 to a maximum of 28, with higher scores indicating worse outcomes.
Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Use of topical corticosteroids
Mean weight (in grams) of topical corticosteroids used by participants during the 12 weeks of the study.
Time frame: From baseline to 12 weeks
Mean change in TOPICOP score
Mean change from baseline to 12 weeks in the Topical Corticosteroid Phobia (TOPICOP) score. The TOPICOP score ranges from a minimum of 0 to a maximum with 100, with higher scores indicating greater levels of phobia.
Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Mean change in gut microbiota
Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in alpha diversity, beta diversity and short chain fatty avid levels measured from stool samples
Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Mean change in skin microbiota
Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in alpha and beta diversity measured from skin swabs
Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Mar 2026, 16 months after the start.
Of 70 phase 2 interventional studies under Eczema, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 16 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of New South Wales